Compare YMT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YMT | MOLN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.7M | 164.2M |
| IPO Year | 2025 | 2021 |
| Metric | YMT | MOLN |
|---|---|---|
| Price | $1.57 | $4.36 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.75 |
| AVG Volume (30 Days) | ★ 54.0K | 4.4K |
| Earning Date | 06-09-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,502,945.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $999.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $3.36 |
| 52 Week High | $6.05 | $5.91 |
| Indicator | YMT | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.51 |
| Support Level | N/A | $4.16 |
| Resistance Level | N/A | $4.44 |
| Average True Range (ATR) | 0.00 | 0.17 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 64.50 |
Yimutian Inc is the largest agricultural B2B platform in mainland China. It provide a comprehensive set of digital solutions to facilitate agricultural product transactions, ranging from searching, matching, to transaction facilitation and settlement. The company pride itself as the go-to platform for merchants by leveraging its inventive technology and industry know-how. Its platform had over 38 million merchants. It has also established approximately 12 offline stores in mainland China to trade agricultural products at cultivation and production sites with sellers and buyers.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.